Malignant Mesothelioma (MM) is a relatively common, rapidly progressive and treatment-resistant malignancy that is associated with exposure to asbestos. Both human patients and mouse models of MM show frequent loss of the neurofibromatosis type II (NF2) gene, and re-expression of NF2 cDNA in Nf2-/- MM cells slows their proliferation and restrains their motility, implying that NF2 plays a causal role in MM. The protein product of the NF2 gene, Merlin, binds to and inhibits p21-activated protein kinases (Paks), enzymes that positively regulate cell cycle progression, survival, and motility. Recent evidence from our laboratories strongly suggests that Pak is required for transformation in cells lacking the NF2 gene. We postulate that loss of Pak function will lead to diminished activation of key Merlin effector pathways in NF2-deficient MM cells as well, and thus could benefit patients with MM. We propose two aims: 1) Using pharmacologic and genetic means to disable Pak function, we will establish the signaling pathways affected by Pak in MM cells, and also identify the key substrates of Paks in these cells that affect cell survival;2) We will cross Nf2f/f;Ink4a/Arff/f mice, which develop MM upon intrapleural injection of Adeno-Cre, with a transgenic mouse that conditionally expresses a specific Pak inhibitor. This experiment will allow us to determine if loss of Pak function affects MM incidence and/or progression, as well as establish the in vivo signaling pathways that mediate this effect. The proposed studies will not only increase our understanding of cardinal signaling pathways, but could establish Paks as suitable targets for therapeutic intervention in this otherwise untreatable disease.
As there is currently no effective medical therapy for MM, a deadly disease associated with asbestos exposure and loss of the NF2 gene, understanding how NF2 functions in cell proliferation, survival, motility, and invasion is a key strategy to identify signaling pathways that might provide useful drug targets in this disease. The NF2 protein product, Merlin, interacts with and inhibits p21-activated kinases (Paks);when Merlin is not expressed, Paks become highly active. Because activated Paks are themselves oncogenic, and, unlike Merlin, are amenable to inhibition by small molecules, we are in a unique position to explore the biological role of Paks in MM and to determine if these enzymes represent suitable targets for therapy.
|Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331|
|Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473|
|Joseph, Giselle A; Lu, Min; Radu, Maria et al. (2017) Group I Paks Promote Skeletal Myoblast Differentiation In Vivo and In Vitro. Mol Cell Biol 37:|
|Semenova, Galina; Stepanova, Dina S; Deyev, Sergey M et al. (2017) Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. Biochimie 135:1-5|
|Semenova, Galina; Chernoff, Jonathan (2017) Targeting PAK1. Biochem Soc Trans 45:79-88|
|Stepanova, Dina S; Semenova, Galina; Kuo, Yin-Ming et al. (2017) An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Res 77:5026-5038|
|Tan, Yinfei; Sementino, Eleonora; Chernoff, Jonathan et al. (2017) Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. Am J Cancer Res 7:1724-1737|
|Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198|
|Rawat, Sonali J; Araiza-Olivera, Daniela; Arias-Romero, Luis E et al. (2016) H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization. Curr Biol 26:1556-1563|
|Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35|
Showing the most recent 10 out of 28 publications